Year-end Sale % OFF 
Abstract
Twelve patients with mycotic infections were treated with itraconazole during a one-year period. Patients had the following conditions: coccidioidomycosis (three), histoplasmosis (three), mucocutaneous candidosis (two), aspergillosis (three), and urinary tract infection due to Torulopsis glabrata (one). The daily dose of itraconazole ranged from 100 to 200 mg. Ten of the 12 cases were assessable. Clinical improvement was observed in six patients, two with coccidioidomycosis, two with mucocutaneous candidosis, one with histoplasmosis, and one with aspergilloma. Four patients did not respond to therapy; two of these patients had aspergillosis, one had histoplasmosis, and one had T. glabrata infection. No adverse effects were attributable to itraconazole.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
